ANNOVIS Alzheimer’s Disease What is the ANNOVIS Alzheimer’s Disease Study? A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD The Goal The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer’s disease in adults aged 55-85. It will also learn about the safety […]
ANNOVIS Alzheimer’s Disease Read More »
Alzheimer’s National Registry for Treatment and Diagnostics(ALZ-NET) (Mild Cognitive Impairment and Alzheimer’s Disease) ALZ-NET collects clinical and safety data about patients being evaluated for memory concerns or receiving new FDA-approved treatments for Alzheimer’s disease, including drugs/medications and devices, and tracks the long-term health outcomes associated with their use in real-world settings. ALZ-NET is a voluntary
IGC Pharma CALMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What
SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria: 50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study
SUVEN CTP3S1502HT6 Read More »
ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria: 50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
